Dendritic cells pulsed with prostate-specific membrane antigen in metastatic castration-resistant prostate cancer patients: a systematic review and meta-analysis
Open Access
- 1 December 2018
- journal article
- review article
- Published by Elsevier in Prostate International
- Vol. 6 (4) , 119-125
Abstract
No abstract availableKeywords
This publication has 50 references indexed in Scilit:
- Immune response, clinical outcome and safety of dendritic cell vaccine in combination with cytokine-induced killer cell therapy in cancer patientsOncology Letters, 2013
- Cellular Immunotherapy Study of Prostate Cancer Patients and Resulting IgG Responses to Peptide Epitopes Predicted From Prostate Tumor-associated AutoantigensJournal of Immunotherapy, 2013
- Cancer immunotherapy via dendritic cellsNature Reviews Cancer, 2012
- Second-generation aptamer-conjugated PSMA-targeted delivery system for prostate cancer therapyInternational Journal of Nanomedicine, 2011
- Sipuleucel-T Immunotherapy for Castration-Resistant Prostate CancerNew England Journal of Medicine, 2010
- The case of the misleading funnel plotBMJ, 2006
- Identification of an HLA‐A*0201‐restricted T‐cell epitope derived from the prostate cancer‐associated protein trp‐p8The Prostate, 2003
- A dual-monoclonal sandwich assay for prostate-specific membrane antigen: Levels in tissues, seminal fluid and urineThe Prostate, 2000
- Dendritic Cells in Cancer ImmunotherapyAnnual Review of Immunology, 2000
- GM-CSF as a systemic adjuvant in a phase II prostate cancer vaccine trialThe Prostate, 1999